{"entity":{"id":"nct06313983","kind":"trial","name":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer","aka":[],"tldr":"A phase 3 trial of Capecitabine and Lapatinib in advanced solid tumours, run by Tianjin Hemay Pharmaceutical Co., Ltd, now recruiting.","summary":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer is a phase 3 interventional study registered as NCT06313983 by Tianjin Hemay Pharmaceutical Co., Ltd, with 339 participants planned, started 2022-01-08 and due to reach its primary completion in 2025-12. Interventions recorded: Hemay022+AI and Lapatinib+Capecitabine.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06313983","url":"https://clinicaltrials.gov/study/NCT06313983"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["capecitabine","lapatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06313983","phase":"3","setting":"A Phase Ⅲ Randomized, Open Label, Parallel, Multicenter To Assess Efficacy and Safety Study of Hemay022 in Combination With AI In Postmenopausal HER2+/ER+ Advanced Breast Cancer Patients Treated With Trastuzumab-containing Regimens","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","enrolled":339,"outcomes":[]},"route":"/trials/nct06313983/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"lapatinib","kind":"drug","name":"Lapatinib","route":"/drugs/lapatinib/"}]}}